{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:28:32Z","timestamp":1777447712048,"version":"3.51.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, health care professionals have made swift accommodations to provide consistent and safe care, including emphasizing remote access to allow physical distancing. Depot medroxyprogesterone acetate intramuscular injection (DMPA-IM) prescription is typically administered by a health care professional, whereas DMPA-subcutaneous has the potential to be safely self-injected by patients, avoiding contact with a health care professional. However, DMPA-subcutaneous is rarely prescribed despite its U.S. Food and Drug Administration approval in 2004 and widespread coverage by both state Medicaid providers and many private insurers. Depot medroxyprogesterone acetate users are disproportionately non-White, and thus the restriction in DMPA-subcutaneous prescribing may both stem from and contribute to systemic racial health disparities. We review evidence on acceptability, safety, and continuation rates of DMPA-subcutaneous, consider sources of implicit bias that may impede prescription of this contraceptive method, and provide recommendations for implementing DMPA-subcutaneous prescribing.<\/jats:p>","DOI":"10.1097\/aog.0000000000004524","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:53:10Z","timestamp":1631235190000},"page":"574-577","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["The Role of Subcutaneous Depot Medroxyprogesterone Acetate in Equitable Contraceptive Care"],"prefix":"10.1097","volume":"138","author":[{"given":"Audrey M.","family":"Burlando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne N.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arden","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea H.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney A.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarita","family":"Sonalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.contraception.2017.06.010","article-title":"Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study","volume":"96","author":"Cover","year":"2017","journal-title":"Contraception"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"739","DOI":"10.15585\/mmwr.mm7020a2","article-title":"Update to U.S. Selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate","volume":"70","author":"Curtis","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.contraception.2018.03.032","article-title":"Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda","volume":"98","author":"Cover","year":"2018","journal-title":"Contraception"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(18)30061-5","article-title":"Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial","volume":"6","author":"Burke","year":"2018","journal-title":"Lancet Glob Health"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.contraception.2017.11.009","article-title":"Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood","volume":"97","author":"Kohn","year":"2018","journal-title":"Contraception"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"e001350","DOI":"10.1136\/bmjgh-2018-001350","article-title":"Self-administration of injectable contraception: a systematic review and meta-analysis","volume":"4","author":"Kennedy","year":"2019","journal-title":"BMJ Glob Health"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/AOG.0b013e31821188ad","article-title":"Continuation and satisfaction of reversible contraception","volume":"117","author":"Peipert","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2307\/2991641","article-title":"Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth","volume":"31","author":"Trussell","year":"1999","journal-title":"Fam Plann Perspect"},{"key":"R15-20250430","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.contraception.2020.09.001","article-title":"An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)","volume":"102","author":"Katz","year":"2020","journal-title":"Contraception"},{"key":"R19-20250430","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.2105\/AJPH.2016.303393","article-title":"Provider bias in long-acting reversible contraception (LARC) promotion and removal: perceptions of young adult women","volume":"106","author":"Higgins","year":"2016","journal-title":"Am J Public Health"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1110855","article-title":"Effectiveness of long-acting reversible contraception","volume":"366","author":"Winner","year":"2012","journal-title":"N Engl J Med"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.contraception.2014.01.025","article-title":"Interest in and experience with IUD self-removal","volume":"90","author":"Foster","year":"2014","journal-title":"Contraception"},{"key":"R22-20250430","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.contraception.2015.02.005","article-title":"Differences in contraceptive use between family planning providers and the U.S. population: results of a nationwide survey","volume":"91","author":"Stern","year":"2015","journal-title":"Contraception"},{"key":"R24-20250430","first-page":"e9207","article-title":"A mother's cry: a race to eliminate the influence of racial disparities on maternal morbidity and mortality rates among Black women in America","volume":"12","author":"Oribhabor","year":"2020","journal-title":"Cureus"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.semperi.2017.04.003","article-title":"Racial and ethnic differences in contraception use and obstetric outcomes: a review","volume":"41","author":"Jackson","year":"2017","journal-title":"Semin Perinatol"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1055\/s-0040-1713852","article-title":"You don't have to be infected to suffer: COVID-19 and racial disparities in severe maternal morbidity and mortality","volume":"37","author":"Minkoff","year":"2020","journal-title":"Am J Perinatol"},{"key":"R27-20250430","first-page":"67","article-title":"The COVID-19 pandemic has increased the care burden of women and families","volume":"16","author":"Power","year":"2020","journal-title":"Sustainability: Sci Pract Pol"},{"key":"R28-20250430","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jmwh.13190","article-title":"Evidence-based guidance for self-administration of injectable contraception","volume":"66","author":"Marx","year":"2021","journal-title":"J Midwifery Womens Health"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:46:05Z","timestamp":1746081965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004524"}},"subtitle":["A Lesson From the Coronavirus Disease 2019 (COVID-19) Pandemic"],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004524","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"2021-03-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}